The purity of recombinant hIL-17F was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-17F and staining overnight with Coomassie Blue.Learn more about how we get our images
The production of mouse IL-6 by 3T3 MEFs WT cultured with increasing concentrations of hIL-17F was assessed. Media from cells incubated with hIL-17F for 24 hours was collected and assayed for mouse IL-6 by ELISA and the OD450-OD650 was determined.Learn more about how we get our images
Recombinant human IL-17F (hIL-17F) Arg31-Gln163 (Accession #NP_443104) was expressed in human 293 cells at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-17F. All lots are greater than 98% pure.
Recombinant hIL-17F contains no "tags" and the nonglycosylated protein has a calculated MW of 14,903. DTT-reduced protein migrates as a 22 kDa polypeptide. Lower mobility in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 38 kDa protein. The expected amino-terminal RKIPK of recombinant hIL-17F was verified by amino acid sequencing.
The bioactivity of recombinant hIL-17F was determined by its ability to induce mouse IL-6 production by 3T3 MEFs WT. The ED50 of each lot is between 30-80 ng/ml.
Less than 0.01 ng endotoxin/1 μg hIL-17F.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-17F. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
IL-17F is a cystine-linked homodimeric pro-inflammatory cytokine produced by TH17 cells, a distinct CD4+ T cell subset (1). IL-17F induces the production of pro-inflammatory cytokines, antimicrobial peptides, and neutrophil chemoattractants such as IL-6, β-defensin, IL-8, CXCL1, and CXCL6 (1,2). As a result, IL-17F may provide an important link between adaptive and the innate immunity. IL-17F binds with high affinity to IL-17RC, expressed primarily in non-hematopoietic tissues, and with lesser affinity to IL-17RA, which is expressed in hematopoietic tissues (3). IL-17F binding activates the ERK1/2 MAP kinase and NF-κB pathways (1,4). IL-17F appears to be involved in mucosal immunity against bacterial infections and possibly some autoimmune conditions (1,5,6).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.